Dr McKay discusses the study she presented at ASCO GU 2026 which looked at data from the IRONMAN advanced prostate cancer registry.

This international real-world study examined how treatments are sequenced before and after the development of metastatic castration-resistant prostate cancer (mCRPC) across 15 countries between 2018–2022.

The study found an underuse of AR pathway inhibitors before mCRPC develops, despite their post-mCRPC dominance. Treatment patterns vary internationally, and the findings highlight an unmet need for earlier optimisation of therapy sequencing in advanced prostate cancer.